MAAT — Maat Pharma SA Share News
0.000.00%
Last trade - 00:00- €20.04m
- €26.65m
- €4.52m
Brief: Maat Pharma Announces EMA Orphan Drug Designation For Maat033
Brief: MaaT Pharma Appoints Karim Dabbagh As Chairman
Brief: MaaT Pharma Q1 Revenue At EUR 0.7 Million
Brief: MaaT Pharma: FDA Lifts Clinical Hold On Phase 3 Investigational New Drug Application For MaaT013
Brief: MaaT Pharma FY Net Loss Widens To EUR 13.7 Million
Brief: Maat Pharma Receives Authorizations For Phase 2b Clinical Trial
Brief: Maat Pharma Reports Cash Position, Receives FDA Response Letter On MaaT013
Brief: MaaT Pharma Says Presents Promising Detailed Results From Completed Phase 1B Trial With MaaT033
Brief: Maat Pharma Q3 Revenue Up At 0.4 Million Euros
Brief: MaaT Pharma Says FDA Maintains Clinical Hold On MaaT013 In U.S.
Brief: Maat Pharma End-June Cash And Cash Equivalents At Eur 38.4 Million
Brief: MaaT Pharma: Positive Results From Study In Blood Cancer Patients
Brief: Maat Pharma Q1 Revenue At 300,000 Euros
Brief: MaaT Pharma FY Operating Loss Widens To EUR 9.0 Million
Brief: Maat Pharma Announces First Patient Dosed In Phase 3 'Ares' Trial
Brief: MaaT Pharma FY Revenue Of EUR 1 Mln
Brief: MaaT Pharma: Positive Interim Engraftment Data For Oral Formulation MaaT033
Brief: Maat Pharma Provides Business Objectives And Expected Milestones For 2022
Brief: Maat Pharma Presents Promising Clinical Data From 76 Patients With Acute Graft-Versus-Host-Disease Treated With Maat013 At 63Rd Ash Annual Meeting